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Abstract
Background: Skeletal muscle is one of the primary tissues involved in the development of type 2 diabetes (T2D).
The close association between obesity and T2D makes it difficult to isolate specific effects attributed to the disease
alone. Therefore, here we set out to identify and characterize intrinsic properties of myocytes, associated
independently with T2D or obesity.
Methods: We generated and analyzed RNA-seq data from primary differentiated myotubes from 24 human subjects,
using a factorial design (healthy/T2D and non-obese/obese), to determine the influence of each specific factor on
genome-wide transcription. This setup enabled us to identify intrinsic properties, originating from muscle precursor cells
and retained in the corresponding myocytes. Bioinformatic and statistical methods, including differential expression
analysis, gene-set analysis, and metabolic network analysis, were used to characterize the different myocytes.
Results: We found that the transcriptional program associated with obesity alone was strikingly similar to that induced
specifically by T2D. We identified a candidate epigenetic mechanism, H3K27me3 histone methylation, mediating these
transcriptional signatures. T2D and obesity were independently associated with dysregulated myogenesis, down-
regulated muscle function, and up-regulation of inflammation and extracellular matrix components. Metabolic network
analysis identified that in T2D but not obesity a specific metabolite subnetwork involved in sphingolipid metabolism was
transcriptionally regulated.
Conclusions: Our findings identify inherent characteristics in myocytes, as a memory of the in vivo phenotype,
without the influence from a diabetic or obese extracellular environment, highlighting their importance in the
development of T2D.
Keywords: Type 2 diabetes, Obesity, Skeletal myocytes, RNA-seq, Gene expression, Gene-set analysis,
Metabolic network
Background
Type 2 diabetes (T2D) is a complex metabolic disease
characterized by increased resistance to insulin in several
tissues, including liver, adipose tissue, and skeletal muscle,
leading to abnormally high blood glucose levels and com-
promised pancreatic insulin secretion [1]. The incidence
of the disease is increasing with epidemic rates and is
currently affecting around 350 million people [2]. Contrib-
uting to the complexity of T2D, a range of risk factors are
associated with and influence the development of this dis-
ease, including genetic and epigenetic components, seden-
tary lifestyle, diet, and obesity [3]. Indeed, most T2D
subjects are obese [4] and the co-occurrence of these two
conditions makes it difficult to study their individual ef-
fects on the cell, in particular that of T2D. There is also
evidence of differences in the onset of T2D in obese and
non-obese subjects [5]. Collectively, the co-occurrence of
obesity in T2D subjects hinders the ability to pinpoint
what truly underlies the etiology of the disease.
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Skeletal muscle is responsible for around 75% of the
glucose uptake that is stimulated by insulin and thus has
a big impact on glucose homeostasis [6, 7]. Insulin re-
sistance in skeletal muscle is considered to be one of the
early key defects in the development of T2D [8]. It is
therefore critical to improve our understanding of the
development of insulin resistance and the molecular
mechanisms taking place in skeletal muscle as a contrib-
uting cause or consequence of T2D. To accomplish this
in a controlled manner, primary differentiated myotubes,
a well-described in vitro model of human skeletal
muscle, can be used [9]. These cells maintain many fea-
tures of the donor phenotype, including genetic and epi-
genetic components, and, importantly, several properties
related to the T2D phenotype have been shown to be
conserved in the in vitro myocyte model [9–14].
Here we implemented a unique experimental design,
using the in vitro myocyte system, which enabled us to
identify and characterize intrinsic properties of myocytes
in association with T2D and obesity, independently. The
detected changes represent properties that are inherited
from muscle precursor cells of the subjects and retained
in myocytes cultured in an environment without influence
from external factors related to the in vivo phenotype
(e.g., varying levels of hormones and cytokines). Therefore,
these properties are hard-wired in their association to
T2D and obesity, and are not a response to the influence
of the surrounding phenotype. In this study, we sought to
analyze these properties in an attempt to identify molecu-
lar drivers of T2D in the skeletal muscle.
Methods
Subjects and phenotype measurements
Participants (n = 24) were selected from a larger cohort [15]
and divided into four groups based on their body mass
index (BMI) and the results of an oral glucose tolerance
test: normal glucose tolerant (NGT)/non-obese; NGT/
obese; T2D/non-obese; and T2D/obese. The four groups
are from here on referred to as controls, OB, T2D, and
T2D&OB, respectively. Subjects gave their informed con-
sent and the study was approved by the Ethical Committee
of Copenhagen and Frederiksberg Council, Denmark. Be-
fore the experimental day, all participants underwent a clin-
ical examination with blood samples. See Additional file 1:
Supplementary material and methods for more details.
Culturing of myocytes and sampling of RNA for RNA-
sequencing
Human muscle biopsies were taken from the vastus latera-
lis muscle with a modified Bergström needle (including
suction) [16] under local anesthesia with 2% lidocaine, as
described in detail previously [11]. Muscle precursor cells
(satellite cells) were isolated and cultured in growth media
and plated in six-well plates for differentiation (see
Additional file 1: Supplementary methods for details). Cul-
tures were fully differentiated at day 5 (>3 nuclei per myo-
tube in ~70% of the cells). The myotubes were stimulated
with insulin (100 nM) and harvested after 0 (before insulin
stimulation), 0.5, 1, or 2 h. Total RNA was extracted using
TRIzol® (Life Sciences) according to the manufacturer’s in-
structions and purified by poly(A) enrichment using Illu-
mina TruSeq RNA.
RNA-sequencing and data preprocessing
The RNA samples were sequenced with Illumina HiSeq
2000 and 2500 instruments, generating on average 68
million paired-end reads per sample. RNA-seq data for
the six base-line (0 h) control samples were already pub-
lished and are available at the Gene Expression Omnibus
(GSE63887). The remaining data for 90 samples have
been deposited under the accession number GSE81965.
The reads were trimmed from adapter sequences and
aligned to the human genome (Ensembl GRCh37.73,
DNA primary assembly) using STAR 2.3.1u [17] and the
corresponding Ensembl gene structure gtf file. The
resulting bam files were indexed and sorted using Sam-
tools 0.1.18 [18]. As input for the differential expression
analysis, gene counts were calculated using HTSeq-
count 0.5.4p3 [19] with default settings.
Differential expression analysis
The Bioconductor [20] R-package limma [21] was used for
differential expression analysis. First, genes were filtered ac-
cording to a cutoff of CPM >0.3 in at least six samples
(roughly equivalent to a read count of 20). Weighted
trimmed mean of M-values (TMM) normalization [22] was
performed using edgeR [23] and the data were then passed
to the voom function in limma [24]. The duplicateCorrela-
tion function was used to handle the correlation of samples
originating from the same subjects [25]. Finally, the limma
workflow for differential expression analysis was run, using
linear modeling and empirical Bayes statistics, implemented
in the functions lmFit and eBayes [26] (see Additional file
1: Supplementary methods for details). All differential ex-
pression analysis results are available in Additional file 2:
Table S1. Correction for multiple testing was performed by
adjusting the p values to control the false discovery rate
(FDR) according to the method described by Benjamini and
Hochberg [27] as implemented in the p.adjust function in
R. The adjusted p values are referred to as q values.
Gene-set analysis
All gene-set analyses (GSAs) were carried out using the
Bioconductor R package piano [28]. Gene-set p values
were calculated using gene-wise permutation (10,000
times) and p values were adjusted for multiple testing (q
values) in the same manner as for the gene-level p
values. Consensus GSA was used by running two GSAs
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in parallel, first with gene-level q values and second with
log2 fold changes as gene-level statistics. The results
were combined so that average q values were obtained
for each gene-set, thus favoring gene-sets with genes dis-
playing both large fold changes and high statistical sig-
nificance. Significant gene-sets were selected using a
cutoff of (average) q < 0.001 (for the so called non-
directional class). See Additional file 1: Supplementary
methods for details.
Reporter metabolite analysis
Metabolite gene-sets were acquired from the myocyte
genome-scale metabolic network iMyocyte2419 [29]. Re-
porter metabolite analysis was performed using the re-
porter features algorithm [30] implementation in piano.
To avoid unspecific metabolite gene-sets, only gene-sets
with 3–50 genes were used in the analysis. Gene-set p
values were adjusted for multiple testing (q values) in the
same way as for the other GSAs. The python package Kiwi
[31] was used through the BioMet Toolbox interface [32]
for visualizing the significant metabolites and their inter-
actions, using a significance cutoff of q < 0.003 and a
shortest path length cutoff of 2. High-degree metabolites
(>73 edges) were removed from the myocyte metabolic
network before visualization. This did not remove any sig-
nificant metabolites, but disconnected oleoyl-CoA from
the subnetwork which otherwise would have been con-
nected through a high-degree metabolite or co-factor.
eQTL analysis
The NCBI GTex eQTL Browser [33] was used for acquir-
ing eQTLs associated with obesity and T2D. These data
were integrated with our results to identify genes that were
both an eQTL and significantly differentially expressed. See
Additional file 1: Supplementary methods for details.
Additional subjects, RNA isolation, and quantitative PCR
In vitro myocytes, cultured as described above (but ex-
cluding insulin stimulation), from an additional set of 12
male subjects (from the same larger cohort as the 24
main subjects, described above) were used for follow-up
analysis using quantitative real-time PCR (qPCR). Four
of the original 24 subjects were also included (one T2D/
non-obese and three NGT/non-obese males), in total
summing up to 16 samples (eight T2D + eight healthy
controls) taken at baseline, i.e., before/without insulin
stimulation (see Additional file 3: Table S2 for subject
characteristics). Total RNA was extracted from myocytes
using TRIzol according to the manufacturer’s instructions.
Total RNA was dissolved in RNase-free water and quanti-
fied using a Nanodrop ND 1000 (Saveen biotech ApS,
Arhus, Denmark). Total RNA (500 ng) was reverse tran-
scribed using the High Capacity Reverse Transcription kit
(Applied Biosystems, Foster City, CA, USA) according to
the manufacturer’s protocol. qPCR was performed in tripli-
cate using the ViiA™ 7 Real-Time PCR platform. The pri-
mer sequences are listed in Additional file 4: Table S3. Data
analysis was performed using the comparative method
(ΔΔCT). PPIA was utilized as an endogenous control.
Results
Characterizing inherent properties of myocytes using
RNA-seq
To study the individual effects of T2D and obesity we
used a factorial design with two levels of each of the main
factors (T2D and obesity). This resulted in four subject
groups, as shown in Fig. 1a: controls (NGT and non-obese
subjects), the T2D group (T2D but non-obese subjects),
the OB group (obese but NGT subjects), and finally the
T2D&OB group (subjects being both obese and T2D).
Obesity was defined as having a BMI of more than 30 kg/
m2. According to these criteria a total of 24 human sub-
jects (three males and three females per group) were se-
lected from a larger cohort, previously described by
Pedersen et al. [15]. The subject characteristics are pre-
sented in Table 1. Muscle precursor cells from the sub-
jects were isolated and differentiated in vitro, under
identical conditions, into myotubes (subsequently referred
to as in vitro myocytes). In principle, the only distinction
between the different in vitro myocytes is that they are de-
rived from precursor cells from subjects with different
phenotypes and genotypes (Fig. 1b). Thus, if differences
can be detected between in vitro myocytes from the differ-
ent groups, those will represent properties that are intrin-
sic to the cells and not directly related to the influence
from varying in vivo extracellular factors.
A hallmark of T2D is increased insulin resistance. In
order to be able to capture both baseline transcriptional
differences and potential differences in transcriptional
responses to insulin, the in vitro myocytes were stimu-
lated with insulin and samples for RNA-seq were taken
at baseline and at 0.5, 1, and 2 h after stimulation, result-
ing in a total of 96 samples.
We performed differential expression analysis using a
linear model that could capture the main effects of T2D
and obesity, as well as their possible influence on each
other. This approach enabled the comparison of the four
subject groups and also included factors adjusting for
the potential influence on gene expression by insulin,
sex, and age. The complete differential expression re-
sults, including FDR-adjusted p values (q values) and
fold changes, are available in Additional file 2: Table S1.
Inherent transcriptional profiles associated with T2D and
obesity are remarkably similar
Insulin had a significant effect on transcription, but
this effect did not differ between the four groups
(Additional file 5: Figure S1). Next, the transcriptional
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signatures associated with T2D and obesity were
assessed by comparing the T2D, OB, and T2D&OB
groups to controls. Distinctive transcriptional changes
were detected in these comparisons (Additional file 6:
Figure S2a), confirming the existence of inherent
properties of myocytes derived from subjects with
T2D and/or obesity. These findings were robust with
regards to using different combinations of factors in
the linear models (Additional file 5: Figure S1).
Hierarchical clustering of the fold changes of the signifi-
cant genes in at least one of the three comparisons re-
vealed a notable similarity in the transcriptional patterns
of the T2D, OB, and T2D&OB groups (Fig. 1c). The Pear-
son correlation of the fold changes was also high (0.67,
0.81, and 0.65) between the three groups (Additional file 6:
Figure S2b). It is remarkable that the inherent transcrip-
tional profile associated specifically with T2D (without
the influence of obesity) was consistent with the profile
a
c
b
Fig. 1 High similarity between the inherent transcriptional profiles associated with obesity and T2D. a The factorial design used to study T2D and
obesity. Each group consists of three females and three males. b Muscle precursor cells were isolated from the subjects and differentiated in vitro. The
cells were stimulated with insulin and samples for RNA-seq were taken at 0, 0.5, 1, and 2 h after stimulation in order to detect inherent transcriptional
profiles associated with the four groups. c Heatmap of the fold changes for genes that were significant in at least one of the three groups compared
to controls. Values are hierarchically clustered (dendrogram not shown), displaying the high consistency between the transcriptional signatures of the
T2D, OB, and T2D&OB groups. (See also Additional file 5: Figure S1 and Additional file 6: Figure S2)
Table 1 Subject characteristics for the RNA-seq dataset
Control OB T2D T2D&OB P value
Sex 3 M/3 F 3 M/3 F 3 M/3 F 3 M/3 F -
Age, years 48–63 41–56 50–63 46–63 0.155
BMI, kg/m2 24.0 ± 0.6b,d 35.2 ± 3.6a,c 24.4 ± 2.7b,d 33.2 ± 2.8a,c 2.04e-07
Fasting glucose (0 h), mmol/l 5.4 ± 0.6c 5.7 ± 0.5 9.0 ± 3.8a 8.1 ± 1.4 0.0156
Glucose (2 h), mmol/l 5.2 ± 1.0c,d 5.5 ± 1.2c,d 18.0 ± 7.3a,b 16.4 ± 3.5a,b 1.12e-05
Insulin (0 h), pmol/l 25 ± 7d 60 ± 33 38 ± 35 79 ± 43a 0.0438
Insulin (2 h), pmol/l 175 ± 123 197 ± 153 281 ± 303 509 ± 376 0.137
HOMA-IR 0.47 ± 0.13d 1.13 ± 0.61 0.81 ± 0.72 1.61 ± 0.83a 0.0347
Cholesterol (total), mmol/l 5.2 ± 0.8 4.9 ± 0.3 5.1 ± 0.7 5.0 ± 0.6 0.918
Cholesterol (HDL), mmol/l 1.7 ± 0.5 1.3 ± 0.3 1.4 ± 0.4 1.2 ± 0.3 0.202
Cholesterol (LDL), mmol/l 2.8 ± 0.5d 3.4 ± 0.6 3.1 ± 0.4 3.6 ± 0.5a 0.0512
Triglycerides, mmol/l 1.0 ± 0.2 1.2 ± 0.8 1.7 ± 0.8 2.1 ± 0.7 0.0586
Free fatty acids (0 h), mmol/l 0.31 ± 0.09c,d 0.44 ± 0.13 0.56 ± 0.22a 0.61 ± 0.07a 0.0078
Free fatty acids (2 h), mmol/l 0.07 ± 0.03 0.07 ± 0.04 0.13 ± 0.05 0.13 ± 0.03 0.0182
Ages are shown as ranges, other values are means ± standard deviations. Differences between means were compared using one-way ANOVA, and post-hoc Tukey’s
test was used for testing pair-wise group differences. Superscripts denote significant difference (p < 0.05) from a) Control, b) OB, c) T2D, and d) T2D&OB. P values
in last column are from the ANOVA F-test
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associated specifically with obesity (without the influ-
ence of T2D). This pattern is apparently also conserved
in in vitro myocytes derived from subjects that are both
obese and diabetic.
In addition, we correlated expression patterns and se-
quence variations in our data, based on known expressed
quantitative trait loci, and identified seven genes (PPARG,
FBN2, JAZF1, ANXA5, RFTN1, IRS1, andMACROD2) po-
tentially influenced by short nucleotide polymorphisms
(Additional file 7: Figure S3).
The transcriptome data indicate an influence from the
specific histone methylation H3K27me3
The presence of inherent transcriptional patterns is
likely mediated by some combination of genetic and
epigenetic mechanisms. To investigate whether there
could be any influence from histone modifications we
performed gene-set analysis (GSA), using gene-sets ac-
quired from the Epigenomics Roadmap project, to iden-
tify histone modification gene-sets that were enriched by
differentially expressed genes. One histone modification
turned out to be significant for all three groups (T2D,
OB, and T2D&OB), namely tri-methylation of lysine 27
on histone 3 (H3K27me3), which was represented by
five gene-sets (Fig. 2). To validate these results, we re-
peated the analysis using histone modification gene-sets
from the ENCODE project, confirming the significance
of the H3K27me3 modification (Additional file 8: Figure
S4a). There was a slight indication of down-regulation
for some of the gene-sets, but in general the H3K27me3
gene-sets showed unspecific regulation, i.e., genes that
have been shown to be associated with H3K27me3 dis-
played a mix of up- and down-regulation in our data. In
addition, we calculated the number of significant genes
Fig. 2 All investigated histone modification gene-sets. Significant gene-sets are marked as either red (up-regulated), blue (down-regulated), or
green (unspecifically regulated). The sets consisting of genes with H3K27me3 marks (determined by separate ChIP-seq experiments) were enriched
by significantly differentially expressed genes, implying that there may be an influence on the observed transcriptional patterns, mediated
through this specific histone methylation. (See also Additional file 8: Figure S4)
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among the H3K27me3 genes and for randomly per-
muted genes sets of the same size (Additional file 8: Fig-
ure S4b). Clearly there is a substantially higher portion
of H3K27me3 genes that are transcriptionally regulated
in T2D, OB, and T2D&OB (compared to controls) than
expected by random chance.
H3K27 methylation patterns can be inherited from the
muscle precursor cells, but also be affected by the activ-
ity of histone methyltransferases and demethylases in
the in vitro myocytes. The H3K27me3 demethylases
KDM6A (UTX) and KDM6B (JMJD3) [34] did not show
significant changes in our differential expression results.
The PRC2 complex is involved in H3K27 methylation
involving the subunits EZH2, RBBP4 (RbAp48), RBBP7
(RbAp46), SUZ12, and EED [35]. Of these, only RBBP4
was found significantly differentially expressed (q =
0.002) displaying a down-regulation in T2D.
Functional characterization of the inherent transcriptional
signatures
To characterize the functions represented by the observed
gene expression profiles we started by exploring a collection
of 50 so-called hallmark gene-sets that have been computa-
tionally and manually curated, refined, and validated [36].
The GSA results for the T2D, OB, and T2D&OB groups
(versus controls) were quite consistent for all three groups
and clearly indicated two significant processes that were
top ranked in all groups and showed a consistent distinct
regulation. First, up-regulation of epithelial–mesenchymal
transition (EMT), and second, down-regulation of myogen-
esis (Fig. 3a; Additional file 9: Figure S5).
To complement this analysis we also ran a Gene Ontol-
ogy (GO) term [37] GSA. These results also supported the
observed consistency in transcriptional profiles of T2D
and obesity, in terms of a high extent of overlapping
a
b
Fig. 3 Functional characterization of the transcriptional signatures. a Significant hallmark gene-sets (see also Additional file 9: Figure
S5). b Significantly up-regulated and down-regulated Gene Ontology (GO) terms (see Additional file 10: Figure S6 for GO terms with
unspecific regulation)
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significant gene-sets between the three groups, but also
highlighted some group-specific GO terms (Fig. 3b;
Additional file 10: Figure S6). The results indicated up-
regulation of genes involved in inflammatory and immune
response (in line with the hallmark gene-sets), and in pro-
cesses involved in the structure and function of the extra-
cellular matrix. The down-regulated GO terms were
almost exclusively related to muscle cell function and
structure, in line with the observed down-regulation of
the myogenesis hallmark gene-set. On the gene level,
there was also a significant (q < 0.05) down-regulation of
the myogenic markers MYOD1, MYOG, TNNI1, MYH2,
and MEF2C in the T2D group (see details in Additional
file 2: Table S1). MEF2C was also significantly down-
regulated in the OB and T2D&OB groups.
Network-dependent analysis reveals changes in
sphingolipid metabolism in association with T2D
As both T2D and obesity are conditions associated with al-
tered metabolism it was of interest to investigate whether
any transcriptional changes related to metabolism occurred.
GSA of metabolic pathways did not, however, identify any
significant pathways. To not be constrained by classic meta-
bolic pathway definitions, a separate analysis was run, iden-
tifying so called reporter metabolites [38]. These are
metabolite gene-sets that are extracted from the topology
of a myocyte genome-scale metabolic network [29]. The
tool Kiwi [31] was used to visualize the significant metabo-
lites and their interactions and connection in the metabolic
network (Fig. 4a). A connected subnetwork of metabolites
was identified, involving a specific part of sphingolipid me-
tabolism (Fig. 4b). This subnetwork was affected by a gen-
eral transcriptional up-regulation in T2D versus controls,
even though individual genes showed mixed directions of
change. The heatmap in Fig. 4c shows all connected genes
underlying the identified network. Even though the signifi-
cantly differentially expressed genes are highlighted, all con-
nected genes contribute to the metabolite gene-set scores,
regardless of an arbitrary cutoff, which is one of the benefits
of GSA.
We also performed qPCR on ten selected genes involved
in pathways and processes identified by the functional
characterization of the RNA-seq expression data, using
material from an additional set of in vitro myocytes from
eight T2D and eight healthy males at baseline, i.e., without
insulin stimulation (Additional file 3: Table S2) [39]. Due
to high variance in these data, only one gene (B3GNT5,
which encodes an enzyme catalyzing the first step of
conversion of lactosylceramide into more complex glyco-
sphingolipids) was found significantly differentially
expressed between the T2D and control groups, with a
fold change consistent with the results from the RNA-seq
data analysis (Additional file 11: Figure S7).
Characterizing differences between T2D and OB
Even though the results point to similar and consistent
transcriptional responses associated with T2D and obesity,
a small number of genes were differentially expressed be-
tween T2D and OB. A majority of these were also signifi-
cant in one of the groups compared to controls
(representing changes driven specifically by either T2D or
OB), whereas a few genes were regulated in different direc-
tions in the two groups compared to controls (Additional
file 12: Figure S8).
GO term and hallmark GSA results (for T2D versus
OB) coincided with gene-sets affected in the comparison
of the three groups with controls (Additional file 9: Fig-
ure S5; Additional file 10: Figure S6). This implies that
most of the differences between T2D and OB reflect dif-
ferences in the extent of regulation of the processes and
functions associated with the similar transcriptional pro-
file that we identified for T2D, OB, and T2D&OB. As an
example of this, myogenesis, which was found down-
regulated in all three groups compared to controls, was
also down-regulated in T2D versus OB, showing that
myogenesis was indeed down-regulated in both T2D and
OB, but more pronounced in T2D.
Discussion
It is well known that obesity is a risk factor for T2D and
that these conditions typically appear together. Even so,
it was remarkable that a myocyte derived from an obese
person with no signs of T2D and a myocyte derived
from a T2D but non-obese person converged on the
same inherent transcriptional patterns, pointing to the
myocytes of these subjects having very similar pheno-
types (Fig. 5a). The few differences between the T2D and
OB groups primarily reflected differences in the extent
of these similar changes from controls (Fig. 5b). The lack
of major differences could be due to reduced statistical
power arising from a small number of biological repli-
cates, and, by increasing the sample size, more distinct
differences could potentially be identified. Nevertheless,
more than 200 genes were still significantly differentially
expressed in T2D versus OB, indicating that the similar-
ities are not solely due to reduced statistical power. We
also found that the clear distinction between NGT and
T2D in the non-obese case was reduced in the obese
case, indicating that obesity promotes an inherent
phenotype similar to that of T2D, perhaps providing a
foundation for developing the disease under certain con-
ditions (Fig. 5c). It is important, however, to point out
that obese subjects (both NGT and T2D) are hyperinsu-
linemic, which partly could explain the observed smaller
differences. The effect of T2D on non-obese subjects
(T2D versus controls) is more pronounced, and thereby
different, than the effect of T2D on obese subjects
(T2D&OB versus OB). This observation is important to
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c
Fig. 4 Reporter metabolite analysis of T2D. a Reporter metabolite analysis was run to identify metabolites significantly affected by differential
expression. This analysis revealed a tightly connected subnetwork of metabolites participating in sphingolipid metabolism that is affected by
transcriptional regulation in T2D. b An overview of the reactions that involve the identified metabolites. c The genes connected to each
metabolite gene-set, together with their individual significance and fold change direction. Significantly differentially expressed genes (q < 0.05) in
T2D versus controls are marked in bold and color. Ceramide (Cer), glucosylceramide (GluCer), lactosylceramide (LacCer), galactosylceramide (GalCer),
digalactosylceramide (DiGalCer), UDP-galactose (UDP-Gal), UDP-glucose (UDP-Glu)
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take into account when conducting research or compar-
ing results between studies that investigate the effect of,
e.g., T2D on subject groups with different BMI levels.
We found a candidate epigenetic histone mark,
H3K27me3, behind the inherent transcriptional landscape
of myocytes derived from obese and T2D subjects.
H3K27me3 has been reported to be associated with tran-
scriptional repression [40–42]. A portion of the H3K27me3
gene-sets were specifically enriched by down-regulated
genes and it is therefore possible that there is an increase of
the H3K27me3 mark in myocytes from T2D, OB, and
T2D&OB subjects. A previous study in adipocytes showed
that a large number of genes can be influenced by genome-
wide histone methylation differences in connection with
T2D and overweight [43]. Nevertheless, as our data indi-
cated a mix of both up- and down-regulation of
H3K27me3 genes, it is plausible that specific changes in
H3K27me3 levels take place in different genomic locations.
H3K27me3 is associated with transcriptional repression of
genes involved in development and differentiation [40, 41]
and the H3K27me3 mark is removed during myogenesis
[44]. Consistently, our analyses revealed down-regulation of
genes involved in myogenesis, muscle development, and
muscle contraction, function, and structure. There was also
a significant down-regulation of myogenic marker genes in
the T2D group. It thus seems like part of the inherent tran-
scriptional profile associated with both T2D and obesity in-
volves down-regulation of genes involved in muscle
development, mediated through differential H3K27 methyla-
tion compared to controls.
Intriguingly, we observed up-regulation, in all three
groups, of genes involved in the function of the extracellu-
lar matrix (ECM), represented by the hallmark EMT gene-
set, and several GO terms, including extracellular matrix,
heparin binding, collagen binding, glycosaminoglycan bind-
ing, and integrin binding. ECM is important in muscle
maintenance and regulation of muscle development and
growth and is essential for myotube formation [45, 46]. A
majority of the components of the ECM are produced by fi-
broblasts [47], but both muscle precursor cells (satellite
cells) and multinucleated myofibers have been shown to
contribute to the production of ECM [48–50]. Perhaps the
up-regulation of genes involved in the ECM in combination
with down-regulation of myogenesis and muscle function is
a compensating mechanism, although this needs to be fur-
ther investigated.
Sphingolipids, a diverse group of metabolites with roles
in cell structure (including the ECM) and signaling, have
previously been implicated in T2D and obesity [51, 52].
Increased sphingolipid production, plasma glycosphingoli-
pid levels, and muscle ceramide levels, in association with
T2D, have been reported in the literature before [53–55].
Inhibition of glucosylceramide synthase, catalyzing the
production of glucosylceramide from ceramide (Fig. 3d),
and thus reducing the production of a number of down-
stream glycosphingolipids, has been shown to result in
improved insulin sensitivity [56]. Other studies have also
reported a correlation between ceramide levels in muscle
and reduced insulin sensitivity [57–59]. Here we found
that the metabolism connecting ceramide and glycosphin-
golipids was transcriptionally up-regulated in myocytes
originating from T2D subjects but kept in an identical in
vitro environment as myocytes originating from control
subjects. This provides evidence for the presence of inher-
ent regulation of this part of metabolism, independent of
circulating levels of, e.g., insulin or sphingolipids, corrob-
orating the importance of sphingolipids in the pathogen-
esis of T2D in skeletal muscle.
Plasma ceramides have also been shown to correlate with
levels of the inflammatory cytokines TNF-alpha and IL6
[54, 60] and have been suggested to be the mediator behind
TNF-alpha-induced insulin resistance [61]. There is thus
a b c
Fig. 5 Summary of the transcriptional patterns across the four subject groups. a The T2D, OB, and T2D&OB groups display similar transcriptional
changes compared with the controls. b The expression differences between T2D and OB mainly reflect differences in the extent of the similar
changes from controls (see also Additional file 12: Figure S8). c The detected differences between T2D and NGT are dependent on the weight
levels of the subjects. The difference between T2D and NGT in non-obese subjects is larger than for obese subjects. Similar observations were
made for the obesity factor
Väremo et al. Genome Medicine  (2017) 9:47 Page 9 of 12
evidence of a link between sphingolipids, insulin resist-
ance, and inflammation. Indeed, chronic low-grade in-
flammation and activation of the immune system have
been shown to be involved in obesity and the pathogenesis
of T2D [62, 63]. The role of muscle inflammation in con-
nection to T2D is not fully understood. Macrophage infil-
tration has been observed in skeletal muscle of obese mice
[64] and increased inflammatory macrophage gene expres-
sion was seen in skeletal muscle of T2D human patients
[65]. In line with this, our analysis of GO term and hallmark
gene-sets identified up-regulation and unspecific regulation
of immune and inflammatory responses in the T2D, OB,
and T2D&OB groups. It is interesting that the in vitro myo-
cytes, which are not in contact with any macrophages, in-
herently expressed immune- and inflammation-related
genes, solely as a consequence of having originated from
muscle precursor cells from subjects with T2D or obesity.
Conclusions
Our study enabled a systematic characterization of the indi-
vidual effects of T2D and obesity on skeletal myocytes. In
particular, by using the in vitro myocyte model we were
able to identify several properties that were inherent to
myocytes originating from T2D and obese subjects, dis-
tinctive from control myocytes cultured in the same envir-
onment. Markedly similar transcriptional profiles were
observed in association with both T2D and obesity, perhaps
as a result of epigenetic modifications inherited from the
muscle precursor cells, reflecting a down-regulation of
myogenesis and muscle function and up-regulation of
genes involved in inflammation and ECM. Using a
network-based approach, independent of classic metabolic
pathway definitions, we were also able to identify up-
regulation of a metabolite subnetwork involved in sphingo-
lipid metabolism. These changes were inherently present as
a molecular memory of the in vivo condition, without the
influence from a diabetic or obese extracellular environ-
ment, highlighting their importance in the progression and
treatment of T2D.
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